Business RisksRisks include lower-than-projected growth of diagnostics services, inability to develop or secure regulatory approval of novel pharmaceuticals, fluctuation of sales in emerging markets and foreign exchange rates, and failure to achieve commercial success due to market size, penetration rate, and competition.
Financial PerformanceOPKO's third quarter top-line performance was a bit light relative to expectations, with revenue coming in lower than estimated.
Revenue DeclineConsolidated total revenues were $173.6M, representing a 3% year-over-year decline and missing the projection of $181M.